

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/047899 A2

(51) International Patent Classification⁷: G01N 33/50

(21) International Application Number:
PCT/US2004/036952

(22) International Filing Date:
4 November 2004 (04.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/518,476 7 November 2003 (07.11.2003) US
60/519,085 10 November 2003 (10.11.2003) US
60/592,926 30 July 2004 (30.07.2004) US

(71) Applicant (for all designated States except US): ACA-
DIA PHARMACEUTICALS INC. [US/US]; 3911 Sor-
rento Valley Road, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NASH, Norman
[CA/US]; 10495 Abalone Landing Terrace, San Diego,
CA 92130 (US). SCULLY, Audra, L. [US/US]; 1469
Sapphire Drive, Carlsbad, CA 92009 (US). GARDELL,

Luls [US/US]; 12360 Carmel Country Road, Apt. #205,
San Diego, CA 92130 (US). OLSSON, Roger [SE/SE];
Klagshamnsvagen 99A, S-2304 Bunkeflo Strand (SE).
GUSTAFSSON, Magnus [SE/DK]; Frederiksvej 47, 1.th.,
DK-2000 Frederiksberg (DK).

(74) Agent: HART, Daniel; Knobbe Martens Olson & Bear
LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: USE OF THE LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING COMPOUNDS EFFECTIVE IN THE
TREATMENT OF PAIN AND INFLAMMATION

**Compound 7 Dose-dependently Prevents Thermal
Hyperalgesia Induced by Carrageenan in M-SD**



Base = Naïve response latency
Compounds were administered 15 min prior to dH₂O or 2% carrageenan (10% i.paw.)
Response thresholds to a noxious thermal stimulus was measured using the 62°C Hot plate test.
Vehicle = 100% DMSO. All n=6.

(57) Abstract: Disclosed herein are compounds that selectively activate the FPRL1 receptor. Further disclosed are methods of alleviating inflammatory responses by regulating key steps in leukocyte trafficking and preventing neutrophil-mediated tissue damage by administering to a subject a therapeutically effective amount of the compounds disclosed herein. In addition, methods of modulating, or specifically agonizing, the FPRL1 receptor by administering an effective amount of the compounds disclosed herein are provided.



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.